Answers are grounded in this paper and cite their sources.
One reason antimicrobial-drug resistance is of concern is its economic impact on physicians, patients, health-care administrators, pharmaceutical producers, and the public. Measurement of cost and economic impact of programs to minimize antimicrobial-drug resistance is imprecise and incomplete. Studies to describe and evaluate the problem will have to employ new methods and be of large scale to produce information that is broadly applicable.
No takes yet. Share an insight, caveat, or question.
John E. McGowan (2001) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: